Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$237.88 USD
+1.40 (0.59%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $237.74 -0.14 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 341 - 360 ( 418 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Demonstrates Compelling Human Proof of Concept Data for ALN-TTR01
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Demonstrates Compelling Human Proof of Concept Data for ALN-TTR01
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Grants InterfeRx Intellectual Property License for the Development of RNAi Therapeutics
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Grants InterfeRx Intellectual Property License for the Development of RNAi Therapeutics
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
REGN Phase II Results Validate Anti-PCSK9 as High Value Target for Treatment of Hypercholesterolemia
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
REGN Phase II Results Validate Anti-PCSK9 as High Value Target for Treatment of Hypercholesterolemia
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New In Vivo Data for miR-21 Further Supports the Power of Regulus? microRNA Technology
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New In Vivo Data for miR-21 Further Supports the Power of Regulus? microRNA Technology
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presents Compelling Early-stage siRNA Data for Hematology Pipeline Programs
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presents Compelling Early-stage siRNA Data for Hematology Pipeline Programs
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Day, Another Way to Drive Value from the ALNY RNAi Platform
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Day, Another Way to Drive Value from the ALNY RNAi Platform
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.